Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl

European Journal of Clinical Pharmacology

Volumn 63, Issue 2, 2007, Pages 159-163

  Harris, Robert Z ^a   Salfi, Margaret ^a   Posvar, Ed ^a   Hoelscher, David ^b   Padhi, Desmond ^a  

^a AMGEN INC   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

Cinacalcet; CYP2D6; Desipramine; Drug interaction; Pharmacokinetics

Indexed keywords

CINACALCET; DESIPRAMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATTENTION DISTURBANCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; FLUSHING; GENOTYPE; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; VOMITING;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DESIPRAMINE; DRUG INTERACTIONS; FEMALE; GENOTYPE; HALF-LIFE; HEADACHE; HUMANS; MALE; NAPHTHALENES; NAUSEA;

EID: 33846427366     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0129-8     Document Type: Article

References (20)

1. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350(15):1516-1525
2. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90(1):135-141
3. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M (2003) The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88(12):5644-5649
4. Silverberg SJ, Faiman C, Bilezikian JP, Shoback D, Rubin MR, Smallridge R et al (2004) Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma. J Bone Miner Res 19(S1):S103
5. Bajpai M, Esmay J, Chi V, Hayashi M, Poppe L, Kumar G (2005) In vitro metabolism and prediction of drug-drug interactions of the calcimimetic agent cinacalcet HCl. Drug Metab Rev 37(Suppl 2):124
6. Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38(2):111-180
7. Preskorn SH, Beber JH, Faul JC, Hirschfeld RM (1990) Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 147(4):532
8. Bell IR, Cole JO (1988) Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol 8(6):447-448
9. Westermeyer J (1991) Fluoxetine-induced tricyclic toxicity: extent and duration. J Clin Pharmacol 31(4):388-392
10. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J et al (1997) Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17(4):284-291
11. Madani S, Barilla D, Cramer J, Wang Y, Paul C (2002) Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol 42(11):1211-1218
12. Hamelin BA, Bouayad A, Methot J, Jobin J, Desgagnes P, Poirier P et al (2000) Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 67(5):466-477
13. Laine K, De Bruyn S, Bjorklund H, Rouru J, Hanninen J, Scheinin H et al (2004) Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Eur J Clin Pharmacol 59(12):893-898
14. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR et al (2003) Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 73(3):170-177
15. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44(4):349-355
16. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14(2):90-98
17. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E (1997) Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 51(5):395-398
18. Amgen Inc. (2004) Sensipar (cinacalcet HCl) prescribing information. Retrieved 11 January 2006 from http://www.sensipar.com/prescribingInfo.jsp
19. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB et al (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16(3):800-807
20. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W et al (2005) Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46(1):58-67